Clinical Trial: IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity

U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07884058) titled 'IGOB131 As A GLP-1 Modulator For Metabolic Disorders In Adults With Obesity' on Oct. 02.

Brief Summary: This clinical trial will investigate the effect of standardized Irvingia gabonensis extract (IGOB131) on GLP-1 dynamics, DPP-4 activity, metabolic parameters, and inflammatory markers in adults with obesity.

The study will compare IGOB131 to a placebo to find out if it exerts any significant metabolic benefits through GLP-1 and DPP-4 modulation, and the reduction of adiposity and systemic inflammation.

Participants will:

Take IGOB131 or a placebo every day for 16 weeks Visit the clinic once every 4 weeks for checkups and tests...